MS Society's (AISM) 2 year "controlled" study of CCSVI which was recently
presented at the Lyon ECTRIMS conference. Directed by the Neurologist Dr.
Giancarlo Comi of the University of Milan and his colleagues, given the name
CoSMo, 35 clinics in Italy participated while 107 clinics were excluded. Early
on Dr Zamboni participated in the study but then pulled out, denouncing the
protocols which he felt would lead to inaccurate, biased results. Apparently the
only diagnostic tool was a Doppler Sonogram undertaken on 1,874 participants,
1,165 with MS, 376 controls and 226 other neurological diseases. Only 3 % of MS
were "positive", slightly less for the controls. Conclusion, the CCSVI MS theory
was pronounced dead and finished, this was their final word. (Interestingly, 89%
of the positive results found at local clinics were declared invalid by the
central examiners.) The Italian MS Society spent $2 million on the study.
This is the first time that a national MS Society has definitively declared the
CCSVI link to MS theory of no further value. (All but one of the principal
researchers have links to major drug companies List to follow.)
It looks like the Semmelweis reflex is alive and well in Italy.
Comi declared having received consultation fees for participating in consulatitive comittees
for Novartis, Teva, sanofi-aventis, Merck Serono, et Bayer Schering. Des
honoraires de conférencier de Novartis, Teva, sanofi-aventis, Merck Serono,
Biogen Dompé, Bayer Schering, et Serono Symposia International Foundation .
Mancardi declared having received honoraries for conferences and
fees for attending meetings as well as financial support for research with Bayer
Schering, Biogen Idec, sanofi-aventis, Novartis et Merck Serono.
Stolz declared having no concerned financial interest."
I posted this on ThisIsMs.com on Oct 20,2012. "phlebologist" commented that the report was given a standing ovation by the Neurologists present. Weren't they happy to believe that a study designed to "prove" Dr. Zamboni wrong had fulfilled their desires. This just goes to show the uphill battle MS patients must fight to get effective treatment. The greatest obstacle of course is financial, since unapproved or "experimental" therapy is not paid by insurance companies or state funded medical systems. And then you have patients unhappy with outcomes threatening lawsuits against interventional radiologists. But courageous vein specialist radiologists continue to treat patients for CCSVI and eventually Neurologists who stubbornly refuse to consider the CCSVI option will be revealed as the Luddites they are.